Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00712491
Other study ID # AMD-002
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received July 8, 2008
Last updated January 8, 2013
Start date September 2008
Est. completion date March 2010

Study information

Verified date July 2010
Source Santen Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date March 2010
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria include, but are not limited to:

- Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration

- Visual acuity of 20/50 to 20/200 in study eye

Exclusion Criteria:

- Any other ocular disease that could compromise vision in the study eye

- History of any prior treatment for choroidal neovascularization in the study eye

- Presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration

Study Design


Intervention

Drug:
Sirolimus
Three subconjunctival injections of 1320 micrograms sirolimus each.
Sirolimus
Three intravitreal injections of 352 micrograms sirolimus each.

Locations

Country Name City State
United States Retinal Consultants of Arizona Phoenix Arizona

Sponsors (2)

Lead Sponsor Collaborator
Santen Inc. MacuSight, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Best-corrected visual acuity by ETDRS 180 days
Secondary Best-corrected visual acuity by ETDRS 60 days, 120 days
Secondary Safety across injection routes Through 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05984927 - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536297 - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Phase 3
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT04005352 - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Phase 3
Withdrawn NCT02873351 - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration Phase 2
Active, not recruiting NCT02802657 - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration Phase 4
Not yet recruiting NCT02864472 - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose Phase 4
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT02035722 - Intravitreal Injections-related Anxiety Phase 2/Phase 3
Completed NCT01445548 - Sirolimus for Advanced Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01048476 - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT01174407 - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration N/A
Completed NCT00345176 - Age-Related Eye Disease Study 2 (AREDS2) Phase 3
Completed NCT02140151 - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Phase 1/Phase 2
Completed NCT02555306 - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration Phase 1/Phase 2
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT03166202 - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed NCT01397409 - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase 2
Recruiting NCT06174181 - Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration N/A